Stereocomplexes for the delivery of anti-cancer agents
US-2024350644-A1 · Oct 24, 2024 · US
Methods for treating or preventing brain infections
US9486442B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9486442-B2 |
| Application number | US-201514612773-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 3, 2015 |
| Priority date | Jun 12, 2008 |
| Publication date | Nov 8, 2016 |
| Grant date | Nov 8, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain barrier to prevent a brain infection.
First claim
Opening claim text (preview).
We claim: 1. A method for treating or preventing a brain infection by a pathogen in a mammal by preventing the pathogen from crossing a blood-brain barrier in the mammal comprising administering a therapeutic amount of a compound that inhibits leukotrienes cellular signaling molecules, wherein said pathogen is selected from the group consisting of Cryptoccous neoformans, Escherichia coli and Streptococcus , and wherein said compound is zafirlukast or pranlukast. 2. The method of claim 1 , wherein the therapeutic amount is from about 0.1 mg/kg to about 100 mg/kg. 3. The method of claim 1 , wherein the mammal has an immuno-compromising disease. 4. The method of claim 3 , wherein the immuno-compromising disease is HIV or AIDS. 5. The method of claim 1 , wherein the mammal has a CD4+ T cell count of less than 50 per μl of blood. 6. The method of claim 1 , wherein the leukotriene molecule is selected from the group consisting of LTC4, LTD4 and LTE4.
Assignees
Inventors
Classifications
Drugs for disorders of the nervous system · CPC title
Quinolines; Isoquinolines · CPC title
having five-membered rings · CPC title
- A61K31/41Primary
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
acyclic · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9486442B2 cover?
- The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain barrier to prevent a brain infection.
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61K31/41. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).